Galapagos Completes Enrollment in Phase 2a Trial Testing GLPG1690 in Diffuse Cutaneous Scleroderma
A Phase 2a clinical trial designed to test Galapagos‘ investigational oral therapy GLPG1690 in people with diffuse cutaneous scleroderma has completed enrolling participants, the company announced. GLPG1690 is a small molecule that targets and blocks autotaxin. This enzyme…